Myeloid-derived suppressor cells as cellular immunotherapy in transplantation and autoimmune diseases

Cell Immunol. 2021 Apr:362:104300. doi: 10.1016/j.cellimm.2021.104300. Epub 2021 Feb 4.

Abstract

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells, which have been characterized for their immunosuppressive capacity through multiple mechanisms. These cells have been extensively studied in the field of tumor immunity. Emerging evidence has highlighted its essential role in maintaining immune tolerance in transplantation and autoimmunity. Because of their robust immune inhibitory activities, there has been growing interest in MDSC-based cellular therapy. Various pre-clinical studies have demonstrated that the adoptive transfer of MDCS represented a promising therapeutic strategy for immune-related disorders. In this review, we summarize relevant studies of MDSC-based cell therapy in transplantation and autoimmune diseases and discuss the challenges and future directions for clinical application of MDSC-based cell therapy.

Keywords: Autoimmune disease; Cellular therapy; Myeloid-derived suppressor cell; Transplantation.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adoptive Transfer / methods
  • Autoimmune Diseases / immunology
  • Autoimmunity / immunology
  • Humans
  • Immune Tolerance / immunology
  • Immunosuppressive Agents / pharmacology
  • Immunotherapy / methods*
  • Myeloid Cells / immunology
  • Myeloid Cells / transplantation
  • Myeloid-Derived Suppressor Cells / immunology*
  • Myeloid-Derived Suppressor Cells / transplantation*
  • Transplants / immunology

Substances

  • Immunosuppressive Agents